Moleculin Biotech
MBRX
24 hedge funds and large institutions have $3.16M invested in Moleculin Biotech in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
4% more funds holding
Funds holding: 23 → 24 (+1)
0.02% more ownership
Funds ownership: 10.42% → 10.43% (+0.02%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
27% less capital invested
Capital invested by funds: $4.32M → $3.16M (-$1.16M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$30.7K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$20.8K |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
+$16.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$13.9K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.69K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Charles Schwab
San Francisco,
California
|
-$46K |
| 2 |
Two Sigma Advisers
New York
|
-$17K |
| 3 |
Renaissance Technologies
New York
|
-$5.79K |
| 4 |
BlackRock
New York
|
-$3.48K |
| 5 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$1K |
MBRX Hedge Fund Activity: Q3 2022 in Review
24 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q3 2022, worth a combined $3.16M — down 27% from $4.32M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new MBRX positions and 3 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $30.7K. The largest seller was Charles Schwab, exiting entirely with an estimated $46K sold.
- 24 institutional investors held Moleculin Biotech (MBRX) as of Q3 2022, up from 23 in Q2 2022.
- Funds reported $3.16M of Moleculin Biotech stock for Q3 2022, down 27% quarter-over-quarter.
- 5 funds opened new Moleculin Biotech positions in Q3 2022 and 3 closed out, a net change of +2 holders.
- The largest Moleculin Biotech buyer in Q3 2022 was Jane Street, an estimated $30.7K added.
- The largest Moleculin Biotech seller in Q3 2022 was Charles Schwab, an estimated $46K sold.
Based on aggregated 13F filings for Q3 2022.